归纳
发表于 2025-3-21 19:28:44
书目名称Cancer影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0221038<br><br> <br><br>书目名称Cancer读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0221038<br><br> <br><br>
indecipherable
发表于 2025-3-21 20:16:33
Kenzo Uchida,Masaya Nakamura,Yoshiaki Toyamaistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clinic. The result of all these medicinal chemistry and biology efforts havebeen captured in the last section that gives an overview of the current status of HDAC inhibitors in theclinic.
Gesture
发表于 2025-3-22 02:05:23
http://reply.papertrans.cn/23/2211/221038/221038_3.png
北极熊
发表于 2025-3-22 04:47:09
HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinicistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clinic. The result of all these medicinal chemistry and biology efforts havebeen captured in the last section that gives an overview of the current status of HDAC inhibitors in theclinic.
导师
发表于 2025-3-22 12:12:07
Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK,bB2 and signals through Raf and MEK to the MAP kinase ERK. Thischapter focuses on the biological rationale, enzymatic and pharmacological properties, and clinical statusof several inhibitors of EGFR/ErbB2, Raf, and MEK1/2. Coverage is given of those compounds that have gainedapproval or are being evaluated in human clinical trials.
pulmonary-edema
发表于 2025-3-22 15:29:26
RIP Kinase-Mediated Programmed NecrosisbB2 and signals through Raf and MEK to the MAP kinase ERK. Thischapter focuses on the biological rationale, enzymatic and pharmacological properties, and clinical statusof several inhibitors of EGFR/ErbB2, Raf, and MEK1/2. Coverage is given of those compounds that have gainedapproval or are being evaluated in human clinical trials.
pulmonary-edema
发表于 2025-3-22 19:03:14
Roles of Microglia in Spinal Cord Injuryed clinical trials. This work covers recent salient achievements in the identificationand development of PI3K/PKB pathway modulators, updating recent reports on this class of potential targetedanticancer drugs.
危险
发表于 2025-3-22 21:28:06
http://reply.papertrans.cn/23/2211/221038/221038_8.png
ineluctable
发表于 2025-3-23 04:45:27
http://reply.papertrans.cn/23/2211/221038/221038_9.png
Adj异类的
发表于 2025-3-23 06:08:11
Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy,rug design, chemical diversity, and biological properties. Noteworthy are a few novel small moleculesthat have enabled preclinical proof-of-concept studies as well as providing promising clinical candidatesfor cancer therapy.